Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
4521 On Other Exchanges
4521 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

kaken pharmaceutical co ltd (4521) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KAKEN PHARMACEUTICAL CO LTD (4521)

Related News

No related news articles were found.

kaken pharmaceutical co ltd (4521) Related Businessweek News

No Related Businessweek News Found

kaken pharmaceutical co ltd (4521) Details

Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. It operates through two segments, Pharmaceuticals and Real Estate. The company offers pharmaceutical and medical devices products, such as Artz, an anti-osteoarthritis drug to treat knee joint pain accompanied by rheumatoid arthritis; Clenafin, a triazole compound for topical medication for onychomycosis; Seprafilm, an anti-adhesive absorbent barrier; Lipidil, an anti-hyperlipidemia product; and Fiblast Spray, a wound-healing drug. Its pharmaceutical and medical devices products also include Procylin, which is used to treat chronic artery occlusive diseases and pulmonary hypertension; Adofeed, a pain- and inflammation-relieving plaster; Mentax, a topical product used to treat superficial mycosis; Ebrantil, a a1 blocker to treat dysuria and hypertension; Berasus to treat pulmonary arterial hypertension; and Clexane, an anticoagulant for the treatment of patients who undergo podiatric or abdominal surgery. In addition, the company provides agrochemicals, including Polyoxins that is used as fungicide; and Pentoxazone, a rice herbicide. Further, it offers animal health products comprising Salinomycin, an anti-coccidial feed additive for chicken; and Colistin sulfate, a polypeptide antibiotic effective against gram-negative bacteria. Additionally, the company is developing KCB-1D for the treatment of periodontitis; KAG-308, a Phase II clinical product to treat Ulcerative colitis; BBI-4000 that is in pre-clinical stage to treat primary focal hyperhidrosis; and SI-657, which is in Phase-III clinical trials to treat Enthesopathy. It primarily focuses on fields, such as inflammation, allergies, and pain relief, as well as fungal infection. The company also rents Bunkyo Green Court commercial facility. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

1,503 Employees
Last Reported Date: 06/26/15
Founded in 1917

kaken pharmaceutical co ltd (4521) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kaken pharmaceutical co ltd (4521) Key Developments

Kaken Pharmaceutical Co. Ltd. to Report Q1, 2016 Results on Aug 05, 2015

Kaken Pharmaceutical Co. Ltd. announced that they will report Q1, 2016 results on Aug 05, 2015

Kaken Pharmaceutical Co. Ltd., Annual General Meeting, Jun 26, 2015

Kaken Pharmaceutical Co. Ltd., Annual General Meeting, Jun 26, 2015., at 10:00 Tokyo Standard Time. Location: Conference Room, 17th Floor, Bunkyo Green Court, Center Office. Agenda: To approve consolidated and non-consolidated financial statements for the year ended March 31, 2015; to approve reverse stock split; to approve election of six Directors and three Corporate Auditors; to approve election of one substitute Corporate Auditor; and to approve payment of bonuses to Directors.

Kaken Pharmaceutical Co. Ltd. to Report Fiscal Year 2015 Results on May 12, 2015

Kaken Pharmaceutical Co. Ltd. announced that they will report fiscal year 2015 results on May 12, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4521:JP ¥8,670.00 JPY -370.00

4521 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4521.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4521 Industry Range
Price/Earnings 25.7x
Price/Sales 4.0x
Price/Book 5.0x
Price/Cash Flow 29.4x
TEV/Sales 4.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAKEN PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at